Protection from hemolytic uremic syndrome by eyedrop vaccination with modified enterohemorrhagic E. coli outer membrane vesicles

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Choi, Kyoung Sub ^a,b   Kim, Sang Hyun ^c   Kim, Eun Do ^a,c   Lee, Sang Ho ^c   Han, Soo Jung ^d   Yoon, Sangchul ^d   Chang, Kyu Tae ^c   Seo, Kyoung Yul ^d  

^a Yonsei University   (South Korea)

^b National Health Insurance Corporation   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EYE DROPS; IMMUNOGLOBULIN; MODIFIED OUTER MEMBRANE VESICLE PROTEIN; NITROGEN; O ANTIGEN; POLYMYXIN B; SHIGA TOXIN; UNCLASSIFIED DRUG; UREA; VACCINE; BACTERIUM ANTIBODY; ESCHERICHIA COLI PROTEIN; ESCHERICHIA COLI VACCINE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE; WILD TYPE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; HEMOLYTIC-UREMIC SYNDROME; IMMUNOLOGY; METABOLISM; MUCOSAL IMMUNITY; PROCEDURES; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD UREA NITROGEN; CREATININE; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; HEMOLYTIC-UREMIC SYNDROME; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; O ANTIGENS; OPHTHALMIC SOLUTIONS; VACCINATION;

EID: 84904489179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100229     Document Type: Article

References (36)

1. Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086. (Pubitemid 40386785)
2. Bielaszewska M, Mellmann A, Zhang W, Kock R, Fruth A, et al. (2011) Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 11: 671-676.
3. Yoon JW, Hovde CJ (2008) All blood, no stool: enterohemorrhagic Escherichia coli O157:H7 infection. J Vet Sci 9: 219-231.
4. Kuehn MJ, Kesty NC (2005) Bacterial outer membrane vesicles and the hostpathogen interaction. Genes Dev 19: 2645-2655. (Pubitemid 41627932)
5. Kim SH, Kim KS, Lee SR, Kim E, Kim MS, et al. (2009) Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim Biophys Acta 1788: 2150-2159.
6. Lee DH, Kim SH, Kang W, Choi YS, Lee SH, et al. (2011) Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming. Vaccine 29: 8293-8301.
7. van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, et al. (2010) Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28: 4810-4816.
8. Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, et al. (2011) A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29: 8381-8389.
9. McConnell MJ, Dominguez-Herrera J, Smani Y, Lopez-Rojas R, Docobo-Perez F, et al. (2011) Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 79: 518-526.
10. Ellis TN, Leiman SA, Kuehn MJ (2010) Naturally produced outer membrane vesicles from Pseudomonas aeruginosa elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components. Infect Immun 78: 3822-3831.
11. Kim SH, Lee SR, Kim KS, Ko A, Kim E, et al. (2010) Shiga toxin A subunit mutant of Escherichia coli O157:H7 releases outer membrane vesicles containing the B-pentameric complex. FEMS Immunol Med Microbiol 58: 412-420.
12. Kim SH, Lee YH, Lee SH, Lee SR, Huh JW, et al. (2011) Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7. FEMS Immunol Med Microbiol 63: 427-434.
13. Leipold MD, Kaniuk NA, Whitfield C (2007) The C-terminal Domain of the Escherichia coli WaaJ glycosyltransferase is important for catalytic activity and membrane association. J Biol Chem 282: 1257-1264. (Pubitemid 47076549)
14. Hitchcock PJ, Brown TM (1983) Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 154: 269-277. (Pubitemid 13115445)
15. Kim SH, Jia W, Bishop RE, Gyles C (2004) An msbB homologue carried in plasmid pO157 encodes an acyltransferase involved in lipid A biosynthesis in Escherichia coli O157:H7. Infect Immun 72: 1174-1180. (Pubitemid 38166705)
16. Gyles CL (2007) Shiga toxin-producing Escherichia coli: an overview. J Anim Sci 85: E45-62.
17. Karmali MA (2004) Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 26: 117-122. (Pubitemid 39118023)
18. Tsuji T, Shimizu T, Sasaki K, Shimizu Y, Tsukamoto K, et al. (2008) Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 26: 469-476.
19. Tsuji T, Shimizu T, Sasaki K, Tsukamoto K, Arimitsu H, et al. (2008) A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 26: 2092-2099.
20. Zhang XH, He KW, Zhang SX, Lu WC, Zhao PD, et al. (2011) Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine 29: 3923-3929.
21. Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, et al. (2007) B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 179: 3371-3379.
22. Pavot V, Rochereau N, Genin C, Verrier B, Paul S (2012) New insights in mucosal vaccine development. Vaccine 30: 142-154.
23. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165: 4778-4782.
24. Zundel E, Verger JM, Grayon M, Michel R (1992) Conjunctival vaccination of pregnant ewes and goats with Brucella melitensis Rev 1 vaccine: safety and serological responses. Ann Rech Vet 23: 177-188.
25. Jayawardane GW, Spradbrow PB (1995) Mucosal immunity in chickens vaccinated with the V4 strain of Newcastle disease virus. Vet Microbiol 46: 69-77.
26. Nagatake T, Fukuyama S, Kim DY, Goda K, Igarashi O, et al. (2009) Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity. J Exp Med 206: 2351-2364.
27. Seo KY, Han SJ, Cha HR, Seo SU, Song JH, et al. (2010) Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J Immunol 185: 3610-3619.
28. Camacho AI, de Souza J, Sanchez-Gomez S, Pardo-Ros M, Irache JM, et al. (2011) Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine 29: 8222-8229.
29. Hu K, Dou J, Yu F, He X, Yuan X, et al. (2011) An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 29: 1455-1462.
30. Okada K, Yamasoba T, Kiyono H (2011) Craniofacial mucosal immune system: importance of its unique organogenesis and function in the development of a mucosal vaccine. Adv Otorhinolaryngol 72: 31-36.
31. Roy K, Hamilton DJ, Munson GP, Fleckenstein JM (2011) Outer membrane vesicles induce immune responses to virulence proteins and protect against colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 18: 1803-1808.
32. Amor K, Heinrichs DE, Frirdich E, Ziebell K, Johnson RP, et al. (2000) Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli. Infect Immun 68: 1116-1124. (Pubitemid 30108499)
33. Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, et al. (2011) Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar typhimurium. Infect Immun 79: 4227-4239.
34. Nagy G, Pal T (2008) Lipopolysaccharide: a tool and target in enterobacterial vaccine development. Biol Chem 389: 513-520. (Pubitemid 351874190)
35. Park KS, Choi KH, Kim YS, Hong BS, Kim OY, et al. (2010) Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS One 5: e11334.
36. Domingues MM, Inacio RG, Raimundo JM, Martins M, Castanho MA, et al. (2012) Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane model systems. Biopolymers 98: 338-344.